Valneva SE (INRLF)
USD 1.98
(0.0%)
USD 1.98
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 52.83 Million EUR | 31.67% |
| 2022 | 36.86 Million EUR | -76.98% |
| 2021 | 160.16 Million EUR | 185.91% |
| 2020 | 56.01 Million EUR | -26.51% |
| 2019 | 76.22 Million EUR | 9.52% |
| 2018 | 69.6 Million EUR | 17.35% |
| 2017 | 59.31 Million EUR | 16.33% |
| 2016 | 50.98 Million EUR | 62.39% |
| 2015 | 31.39 Million EUR | 58.74% |
| 2014 | 19.77 Million EUR | 41.92% |
| 2013 | 13.93 Million EUR | 306.21% |
| 2012 | 3.43 Million EUR | -3.11% |
| 2011 | 3.54 Million EUR | 90.79% |
| 2010 | 1.85 Million EUR | 185.89% |
| 2009 | -2.16 Million EUR | -421.1% |
| 2008 | 673 Thousand EUR | 182.37% |
| 2007 | -817 Thousand EUR | -150.97% |
| 2006 | 1.6 Million EUR | -36.79% |
| 2005 | 2.53 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 14.59 Million EUR | -118.5% |
| 2024 Q1 | 10.59 Million EUR | -33.1% |
| 2023 Q4 | 15.83 Million EUR | -7.4% |
| 2023 Q2 | 6.87 Million EUR | -47.21% |
| 2023 Q3 | 17.09 Million EUR | 148.64% |
| 2023 FY | 48.53 Million EUR | 31.67% |
| 2023 Q1 | 13.02 Million EUR | 226.31% |
| 2022 Q2 | -86.24 Million EUR | -1179.66% |
| 2022 Q1 | 7.98 Million EUR | -96.8% |
| 2022 FY | 36.86 Million EUR | -76.98% |
| 2022 Q4 | -10.31 Million EUR | -108.22% |
| 2022 Q3 | 125.43 Million EUR | 245.44% |
| 2021 Q1 | 8.56 Million EUR | -73.49% |
| 2021 Q2 | 4.15 Million EUR | -51.46% |
| 2021 FY | 160.16 Million EUR | 185.91% |
| 2021 Q4 | 249.9 Million EUR | 343.9% |
| 2021 Q3 | -102.46 Million EUR | -2564.21% |
| 2020 Q2 | 3.63 Million EUR | -84.3% |
| 2020 Q4 | 32.31 Million EUR | 1155.95% |
| 2020 FY | 56.01 Million EUR | -26.51% |
| 2020 Q1 | 23.13 Million EUR | -18.08% |
| 2020 Q3 | -3.06 Million EUR | -184.23% |
| 2019 Q2 | 8.79 Million EUR | -61.15% |
| 2019 Q4 | 28.24 Million EUR | 70.42% |
| 2019 FY | 76.22 Million EUR | 9.52% |
| 2019 Q1 | 22.62 Million EUR | -3.85% |
| 2019 Q3 | 16.57 Million EUR | 88.52% |
| 2018 Q1 | 19.04 Million EUR | 29.15% |
| 2018 FY | 69.6 Million EUR | 17.35% |
| 2018 Q4 | 23.53 Million EUR | 111.49% |
| 2018 Q3 | 11.12 Million EUR | -30.03% |
| 2018 Q2 | 15.9 Million EUR | -16.48% |
| 2017 FY | 59.31 Million EUR | 16.33% |
| 2017 Q4 | 14.74 Million EUR | -2.69% |
| 2017 Q2 | 14.29 Million EUR | -5.46% |
| 2017 Q3 | 15.15 Million EUR | 5.97% |
| 2017 Q1 | 15.12 Million EUR | 16.91% |
| 2016 Q1 | 10.82 Million EUR | -7.46% |
| 2016 FY | 50.98 Million EUR | 62.39% |
| 2016 Q4 | 12.93 Million EUR | 28.02% |
| 2016 Q3 | 10.1 Million EUR | -40.98% |
| 2016 Q2 | 17.12 Million EUR | 58.14% |
| 2015 Q2 | 5.79 Million EUR | 33.11% |
| 2015 Q1 | 4.35 Million EUR | -3.24% |
| 2015 FY | 31.39 Million EUR | 58.74% |
| 2015 Q4 | 11.69 Million EUR | 22.54% |
| 2015 Q3 | 9.54 Million EUR | 64.69% |
| 2014 Q4 | 4.5 Million EUR | -7.16% |
| 2014 Q3 | 4.84 Million EUR | -25.5% |
| 2014 Q1 | 3.92 Million EUR | 53.74% |
| 2014 FY | 19.77 Million EUR | 41.92% |
| 2014 Q2 | 6.5 Million EUR | 65.91% |
| 2013 Q2 | 3.44 Million EUR | 265.26% |
| 2013 Q3 | 7.2 Million EUR | 108.79% |
| 2013 Q1 | -2.08 Million EUR | -333.18% |
| 2013 FY | 13.93 Million EUR | 306.21% |
| 2013 Q4 | 2.55 Million EUR | -64.57% |
| 2012 Q4 | 895 Thousand EUR | -13.28% |
| 2012 Q3 | 1.03 Million EUR | 0.0% |
| 2012 FY | 3.43 Million EUR | -3.11% |
| 2011 FY | 3.54 Million EUR | 90.79% |
| 2010 FY | 1.85 Million EUR | 185.89% |
| 2009 FY | -2.16 Million EUR | -421.1% |
| 2008 FY | 673 Thousand EUR | 182.37% |
| 2007 FY | -817 Thousand EUR | -150.97% |
| 2006 FY | 1.6 Million EUR | -36.79% |
| 2005 FY | 2.53 Million EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | -252.27% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -1703220.438% |
| SQZ Biotechnologies Company | 9.79 Million USD | -439.483% |
| Evofem Biosciences, Inc. | 11.7 Million USD | -351.367% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 55.639% |
| Mesoblast Limited | -35.16 Million USD | 250.242% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 154820.351% |
| Genus plc | 178.7 Million USD | 70.433% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -12781.889% |
| Marizyme, Inc. | 457.7 Thousand USD | -11443.974% |
| ContraFect Corporation | -154 Thousand USD | 34409.74% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 480436.364% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 105774.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -68733.131% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -80287.354% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 13735.32% |
| MultiCell Technologies, Inc. | 49.32 USD | -107130881.346% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | -31.223% |
| EV Biologics, Inc. | 48.9 Thousand USD | -107951.125% |
| Q BioMed Inc. | -8988.00 USD | 587961.593% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | -87.001% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 342663.537% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 75.995% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -75381.429% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 42624.406% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -84811.452% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 1067083.037% |
| Arch Therapeutics, Inc. | -2439.00 USD | 2166438.663% |
| IMV Inc. | -962.29 Thousand USD | 5590.711% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -37506.406% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 54283.459% |
| GB Sciences, Inc. | -624.00 USD | 8467567.949% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 61518.375% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | 99.301% |
| Halberd Corporation | -208.00 USD | 25402503.846% |
| Enzolytics Inc. | 30.7 Thousand USD | -171962.655% |
| Resverlogix Corp. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | -3793.252% |
| SYBLEU INC | 11.69 Thousand USD | -451652.736% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -10852.194% |
| argenx SE | 1.1 Billion USD | 95.233% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 304.81% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -8458.207% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 87.099% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 596723.758% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | -19.115% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 4728.442% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -5247.977% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | -449.755% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 63114.466% |
| BioStem Technologies, Inc. | 15.42 Million USD | -242.545% |
| ONE Bio Corp. | 20.12 Million USD | -162.538% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 446546.979% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 109586.313% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -29825.804% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -29825.804% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 10369.383% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | -630.13 Thousand USD | 8484.989% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 182296.552% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -11640.434% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 16637.04% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | -1046.636% |
| Bioxytran, Inc. | -8285.00 USD | 637842.909% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 14265.416% |
| Neutra Corp. | 14.33 Thousand USD | -368487.374% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 64535.366% |
| PureTech Health plc | -1.6 Million USD | 3396.132% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 5377.177% |
| IXICO plc | 3.27 Million USD | -1515.81% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 7713.401% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 3050.14% |
| CSL Limited | 7.7 Billion USD | 99.314% |
| Cellectis S.A. | 18 Thousand USD | -293438.889% |